Day: August 11, 2023

SINGAPORE, Aug. 11, 2023 (GLOBE NEWSWIRE) — Bitdeer Technologies Group (NASDAQ: BTDR) (“Bitdeer” or the “Company”), a world-leading technology company for the cryptocurrency mining community, today announced its unaudited financial results for the second quarter ended June 30, 2023. Linghui Kong, Chief Executive Officer of Bitdeer, commented, “During the second quarter of 2023, our total revenues increased by 5% year over year to $93.8 million, demonstrating the resilience of our unique business model and our strategic execution capabilities. At the same time, we continued to advance our initiatives to bolster and grow our business, as we delivered year-over-year increases in aggregate electrical capacity and total hash rate under management. On the infrastructure front, we forged ahead with our efforts to expand our global footprint...

Second Quarter Financial Results (in thousands) Q2 23 Q2 22 YOYChange Q2 23            YTD Q2 22 YTD YOYChangeTotal Revenues $ 4,493   $ 4,699 (4.4 %) $ 8,977 $ 9,247 (2.9 %)Operating Income   149     1,040 (85.7 %)   378   1,914 (80.3 %)Income Before Provision for Taxes   88     1,148 (92.3 %)   298   2,013 (85.2 %)Net (Loss) Income   (14 )   921 (101.5 %)   145   1,660 (91.3 %)Gross Billings*   17,541     17,604 (0.4 %)   35,128   34,249 2.6 %EBITDA*   144     1,197 (88.0 %)   406   2,124 (80.9 %)Adjusted EBITDA*   230     1,142 (79.9 %)   534   2,130 (74.9 %)Pre-Corporate EBITDA*   476     1,364 (65.1 %)   1.024   2,606 (60.7 %)*Non-GAAP measures referenced are detailed in the disclosures at the end of this release.DALLAS, Aug. 11, 2023 (GLOBE NEWSWIRE) — Wilhelmina International, Inc....

HOUSTON, Aug. 11, 2023 (GLOBE NEWSWIRE) — Nauticus Robotics, Inc. (“Nauticus” or the “Company”) (NASDAQ: KITT), a developer of autonomous robots using artificial intelligence for data collection and intervention services to the ocean industries, today announced results for the second quarter ended June 30, 2023. HighlightsSigned a contract with Shell plc (NYSE: SHEL) for an initial project in the Gulf of Mexico Princess Field. Pending success, this contract could lead to multi-million dollars worth of additional contracts over the next few years. Signed a contract with Petrobras (NYSE: PBR), one of the world’s largest energy companies, to deploy Aquanaut, the Company’s autonomous subsea robot, to support Petrobras’ offshore activities. The contract opens up a potential market opportunity of more than $100 million per year for...

– GeneFab transaction provides access to clinical manufacturing and extends cash runway into Q4 2024 – – IND for SENTI-202, potentially the first Logic Gated CAR-NK treatment for AML, on track for 2H 2023 – –  Cash, cash equivalents, and short-term investments of $59.6 million as of June 30, 2023 – SOUTH SAN FRANCISCO, Calif., Aug. 11, 2023 (GLOBE NEWSWIRE) — Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases using its proprietary Gene Circuit platform, today reported financial results for the second quarter of 2023. “With this month’s transaction establishing our new clinical manufacturing partner, GeneFab, Senti has a sharpened focus on advancing our internal oncology pipeline and partnered programs,”...

Revenue in Line with Prior Financial Guidance Continued Progress with CMS in Establishment of Medicare Benefit Category for Exoskeletons Pending Acquisition of AlterG Expected to Contribute to ReWalk Financial Results Starting in Q3’23 MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILLIT, Israel, Aug. 11, 2023 (GLOBE NEWSWIRE) — ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”), a leading provider of innovative technologies that enable mobility and wellness in rehabilitation and daily life for individuals with neurological conditions, today announced its financial results for the three and six months ended June 30, 2023. Highlights of the Second Quarter of 2023 include:Total revenue for the second quarter of 2023 was $1.3 million, compared to $1.6 million for the second quarter of 2022. Total revenue for the six months...

Phase I/2a clinical trials initiated: VMT-α-NET for neuroendocrine tumors, and VMT01 for melanoma. Preliminary results from initial cohorts expected by end of 2023. First patient dosed in Phase 1/2a dose escalation trial of VMT01 for treatment of MC1R-positive metastatic melanoma.RICHLAND, Wash. and CORALVILLE, Iowa, Aug. 11, 2023 (GLOBE NEWSWIRE) — Perspective, Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy powering expanding treatment options for multiple cancers, reports second quarter financial results for the period ended June 30, 2023 and recent business highlights. “We made substantial progress on our pipeline during Q2 2023 with the initiation...

CHERRY HILL, N.J., Aug. 11, 2023 (GLOBE NEWSWIRE) — The Real Good Food Company, Inc. (NASDAQ: RGF) (“Real Good Foods” or the “Company”), a leading health and wellness frozen and refrigerated foods company, today reported financial results for its second quarter ended June 30, 2023. Management Commentary Bryan Freeman, Executive Chairman, said: “I am pleased to report a significant acceleration in sales growth this quarter, led by the unmeasured channel, which was up 61% on a year-over-year basis driven by strong velocity growth, as well as new customer wins. Moreover, we gained momentum on the top-line up each month in the second quarter and growth has continued to accelerate into the third quarter. We now have eight high velocity items that participate in seven categories and two temperature states in the unmeasured channel,...

Presented positive initial safety and efficacy data from the BEACON trial at the European Hematology Association (EHA) Congress in June 2023; data from all patients in BEACON to be presented year-end 2023 Initiated a phase 1/2 study of bitopertin in patients with Diamond-Blackfan Anemia who have failed corticosteroid treatment Enrolling patients in two separate Phase 1b/2 studies for DISC-0974, one in patients with anemia of chronic kidney disease who are not receiving dialysis (NDD-CKD) and one in patients with myelofibrosis and anemia; initial data from both trials expected by year-end 2023 Strengthened financial position through a $158 million upsized public offering; ended Q2 with approximately $378 million in cash that is expected to fund operations well into 2026WATERTOWN, Mass., Aug. 11, 2023 (GLOBE NEWSWIRE) — Disc Medicine,...

Company maintains strong cash position of $205 million SOUTH SAN FRANCISCO, Calif., Aug. 11, 2023 (GLOBE NEWSWIRE) — RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the second quarter and the six months ended June 30, 2023. “We continue to remain focused on our Phase 2 trials for RPT193 in atopic dermatitis (AD) and asthma. We anticipate reporting top-line data from our Phase 2b trial in AD in mid-2024 and we continue to enroll our Phase 2a trial in asthma. These are the first two indications in what we believe will be a significant franchise for our promising oral small molecule drug...